CellectGen wins SBIR grant for saliva-based periodontal test
What's the deal? CellectGenDealroom has a profile for this one. Try Dealroom → has received a Small Business Innovation Research (SBIR) grant to develop a saliva-based, point-of-care diagnostic for periodontal disease. The Frederick, Maryland company is building the platform with antibody developer Kemp Proteins and lateral-flow specialist DCNDx.
What's the endgame? The platform measures different molecular forms of an enzyme tied to the breakdown of periodontal tissue, aiming to flag active disease before irreversible damage appears. Existing saliva tests mostly track bacterial or host biomarkers rather than tissue destruction itself.
Why now? About 42% of US adults over 30 have periodontal disease, a leading cause of adult tooth loss linked to an estimated $154 billion in direct and indirect costs. Yet clinicians still struggle to identify active disease early.
Who does what? Kemp Proteins developed and validated monoclonal antibodies that distinguish between the enzyme forms — a problem that long lacked antibodies with the needed specificity. Carlsbad-based DCNDx builds those reagents into a rapid lateral-flow test targeting quantitative results in under 15 minutes, for chairside and at-home use.
"Our platform will help clinicians answer three critical questions: What is the level of active tissue destruction? What is the patient's risk of future disease progression? And is the current therapy working?" said Robert Gellibolian, chief executive officer of CellectGen.
"Diagnostics are only as strong as the reagents behind them," said Mike Keefe, chief executive officer of Kemp Proteins.
What could go wrong? The grant funds development, not a market-ready product. Recent research casts chairside oral-fluid tests mainly as adjuncts for risk assessment and monitoring — not replacements for standard periodontal exams — with variable performance across assays. No validation results or launch timeline have been disclosed.
The signal: The collaboration reflects a broader push toward decentralised, oral-fluid diagnostics that move testing closer to the patient. For now, CellectGen's effort is a development milestone rather than evidence of a market-ready test or a major financing event.
Read more: prnewswire.com
Image credit: Generated with Gemini
